<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 56 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page55.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=56">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 56 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 56</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=56"><img src="../thumb/56.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.5.3                                                  2020-04 / 25
       adrenerg.block.eff.meds., condits. elev.core body temp., sympts.of   Side effects: Cholinerg.syndr.poss.with discont., neurolept.malign.  sympt.can deterior./arise aft.treatm.discont., elev.AST&/ ALT lev.,
       intest.obstruct./ Reye’s syndr., brain tumour & overdose poss.mask.   syndr., treatm.emerg.dyskines., seiz., hyperprolactinaem., hypergly-  S&S of hepat.impairm., pre-exist. condits. assoc with limit.hepat.
       due to anti-emet.eff.observ., excret.in breast milk, no data on switch.to   caem.somet. assoc.with ketoacidos./hyperosmol.coma or death, bld.  funct.reserve, concom. potent.hepatotox.meds., period. assessm. of
       other antipsychot., incr. mortality & cerebrovasc.event risk, no exper.of   dyscras., allerg./skin react., weight gain, elev. cholest./gluc./triglycer./  transaminas.recomm.in hepat.dis. pts., discont.treatm.if hepatit.di-
       treat.schizoaffect.disord.for &gt;4 wks., identif.poss. VTE risk fact.bef.&   ALT/AST lev., incr.appet., glucosur., diab.exacerbat., hypotherm., CNS   agn., incr.diab. preval.in schizophren.pts., monit.exist.diab.for worsen.
       dur.treatm.& undertak. preventativ.meas., IFIS syndr.dur.catar.surg.  effs., dizzin., akathis., parkinson., dyston., bradycard., QTc prolong.,   gluc.contr., monit.pts.start.treatm.at risk of diab.for hyperglycaem.
       Drug interactions: Meds.known to prolong QT interv., other   ventr.tachycard./fibrillat., sudd. death, orthostat.hypotens., thrombo-  sympt., fast.bld.gluc.if hyperglycaem.develops, some requir.contin.
       concom.centr.act.meds., may antagon. eff.of levodopa & other   embol., GI disturbs., pancreatit., hepatit., alopec., rhabdomyolys., urin.  anti-diabet.treatm.despite Oleanz discont., predispos. risk fact.in
       dopamine agonists, addit.hypotens.eff.with meds.hav.this potent.,   diffic., priapism, galactorrh., asthen., fatig., oed., oesophag. dysmotil./  elderly, smokers, dos.modific.necess. in cases where olanzapine
       meds.known to low.seiz.threshold, absorpt. affect.by meds.affect.  aspirat., CV adverse events in elderly pts.with dement.-relat. psychos.  metab.slow., concom. meds.known to incr.QTc interv./congenit.long
       GIT transit time, carbamazepine & other induc.may decr.plasma   Special precautions:  Effectiven..for long.than 6 wks.not est.in   QT syndr./CHF/card.hypertrophy/hypokalaem.& hypomagnesaem.,
       lev., addit.eff.with oral risperidone  control.stud., lact.intol., per. assessm. advis.for maint.treatm.& con-  admin.concom.activ.charc.at least 2 hrs.bef./aft., monit.pts.on con-
       MYLAN QUETIAPINE, (Mylan) Xixia [P/S]  tin.at low. dos.need.to maint.remiss., pass.into breast milk, discont.  com. carbamazepine/ omeprazole/rifampicin, pts. receiv. meds. that
                                     grad., elev.prolact.lev.dur.chron.admin., discont.if any clinic.NMS
       Quetiapine.                   manifestat./high fev. observ., seiz.hist./condits.assoc.with seiz.thresh.   low.BP by mechanisms other than alpha-1 adrenerg.antagon., subst.
                                                                  inhibit./ induc.CYP1A2 isoenzyme, incr.hallucinat.in Parkinson’s pts.,
       Indications: Schizophren., manic episod.assoc. with bi-polar disord.   low., consid.dos.reduct./discont.if tard.dyskines. S&S devel., longt.
       for which safety & effic. beyond 12 wks. not demonstrat.  high-dos.ther., elderly, hepat. impairm., pre-exist.condits.assoc.with   symptom.prostat.enlargem., narrow-angl.glauc., paralyt.ileus/relat.
                                                                  condits., rec.MI hist., unstab.heart dis., card.pts., cont. aspartane,
       (S5) TABS. 41/2.6.5/0951, 0952, 0954, 0955
       716668-001: 25 mg, 100, R254,12  liv.impairm., concom. hepatox.meds., per.LFT in signif.hepat. dis.,   reg.BP monit.of pts.&gt;65 yrs., leucopen./ neutropen., meds.induc.bone
                                                                  marrow depress./ toxic., bone marrow depress.caus.by concom. illn./
                                     pts.≥ 80 yrs., concom.benzodiazepin./other centr.act. agents & al-
       716670-001: 100 mg, 90, R432,55
       716671-001: 200 mg, 60, R444,44  coh., pulm.condits., monit. exist. diab.for worsen.gluc.contr./pts.at   radium ther./chemother., hypereosnophil. condits., myeloproliferat.
                                                                  dis., condits.contrib.to core body temp.elev., aspirat. pneumon.risk
                                     risk for diab. mellit.developm., monit.pts.start.treatm.at risk of diab.
       716672-001: 300 mg, 60, R543,22
       Dosage: Adults: Admin.twice dly.  for hyperglycaem.sympt.in which case to undergo fast.bld.sugar   as oesophag.dysmotil.& aspirat. assoc.with antipsychot., monit.high
                                     test., some pts.req. contin. of anti-diabet.treatm.desp.ther.discont.,
       Schizophren: Tot.dly.dos.for 1  4 days: Day 1: 50 mg, day 2: 100 mg,   risk suic.pts., predispos.risk fact.in elderly with dement.relat. psychos.
                    st
       day 3: 200 mg & day 4: 300 mg. Titr.dos.from 4  day to effect.dos.  concom. meds.incr.QTc interv.esp.elderly/ congenit. long QT syndr./  to incr.mortality incl. &gt;80 yrs./sedat./ concom. benzodiazepines &
                           th
                                     CHF/card.hypertrophy/ hypokalaem./ hypomagnesaem., concom.BP
       range of 300-450 mg/day. Adjust.dos.within 150-750 mg / day range   pulm.condits., elderly with dement.taking stroke risk into account.
       depend.on clinic.response & tolerab.  lower. meds.other than alpha-1 adrenerg.antagon., symptomat. pros-  Drug interactions: CNS eff.enhanc.of other CNS depress.& alcoh.,
       Bipol.disord.assoc.manic episod: Tot.dly.dos. for 1  4 days: Day   tat.enlargem., paralyt.ileus & relat. condits., rec.MI, unstab.card.dis.,   may antagon.effs.of levodopa & dopamine agonists, poss.neutropen.
                              st
       1: 100 mg, day 2: 200 mg, day 3: 300 mg & day 4: 400 mg. Furth.dos.  aspirat. pneum. risk, condits.contrib.to elev.core body temp., supervis.  with valproate, may enhanc.effs.of cert. antihypertens., QTc prolon-
       adjustm. up to 800 mg/day by day 6 in increm.of no great. than 200   suicide risk pts., discont.ther.if hepatit. diagn., low leucocyte &/neu-  gat.risk with meds. known to cause QTc prolongat., pharmakin.effs.
       mg/day. Adjust dos.accord.to clinic. respon. & tolerabil.with range of   troph.count, meds.-induc.bone marr.depress./toxic.hist., bone marr.   with subst.that induc./inhib.CYP1A2, activat. charc. reduc.bioavail.,
       200-800 mg/ day. Usual effect.dos.: 400-800 mg/day.  depress.caus by concom.illn./radiat.-/chemother., hypereosinophil.  fluoxetine incr.conc.& decr.clear., smok./carbamazepine/omeprazole
       Elderly: Init.25 mg/day, theraft.incr.dly.dos.in increm. of 25-50 mg.to   condits.with myeloproliferat. dis., activ.charcoal admin.2 hrs. bef./   & rifampicin.low.plasma lev., potent.CYP1A2 inhibit.poss.decr.clear.
       an effect.dos.poss.low. than young.pts.  aft.Olawin, concom.fluoxetine not recomm., consi d.low.start.dos.  OLEXAR, Cipla-Medpro [P/S]
       Contraindications: Safety in pregn.& lactat. not est., safety & ef-  with fluvoxamine/other CYP1A2 inhib.  Olanzapine.
       fic.in childr.& adolesc.und. 18 yrs. not est., safety in advanc.liv.& ren.   Drug interactions: May antagon.effs.of levodopa & dopamine ago-  Indications: Psychot.disords.(incl.schizophren.), ac.mod.to sev. ma-
       impairm. not est., not indic.for elderly pts.with dement.exhibit.behav.  nists, poss. enhanc.effs.of cert. antihypertens., pharmacokinet.affect.  nia, prev.recurr.of manic/ depress. episod.of bipol.disord.
       disturbs., co-admin.with azole antifung./macrolide antibiot./HIV prot.   by subst. induc./ inhib./act.as substr.to isoenzym. CYP1A2, poss.an-  (S5) TABS, 37/2.6.5/0316, 0317, 0318
       inhibits., Lapp-Lact.defic., gluc-galact. malabsorpt.  tagon.effs.of direct./indir.dopamine agon., reduc.plasma conc.with   715657-001: 2,5 mg, 30, R314,82
       Side effects: Hyperglycaem.sometimes extreme assoc. with ketoaci-  valproate, incr.trem. incid./ dry mouth/weight gain/incr.appet.with   715658-001: 5 mg, 30, R467,70
       dos./hyperosmol.coma/death, bld.disords., hypersens.reacts.incl.  Li/valproate, metab.poss.induc.by smok.& carbamazepine, reduc.  715659-001: 10 mg, 30, R608,00
       anaphylax., Stev.John.syndr., diab.mellit./exacerbat.of pre-exist.  bioavail.with activat.charc., CYP1A2 inhibit.incl.fluvoxamine reduc.  Dosage: Admin.as once-a-day dos. Safety of dos. above 20 mg/
       diab., psych.disords., somnol., dizzin., headache, anx., syncope, ex-  clear., fluoxetine incr.conc.& decr.clear.  day not eval.
       trapyramid.sympt., seiz., tard.dyskines., neurolept.malign.syndr.,   OLEANZ, Ranbaxy [P/S]  Psychot.disords: Init. 5-10 mg/day with target dos.of 10 mg/day
       dry eyes, blurr.vis., eye lens chang.with longterm use, ear/abdom./  Olanzapine.  within several days. If indic. dos.adjustm.of 5 mg increm/decrem.
       back/chest pain, tachycard., QTc prolongat., orthostat.hypotens.esp.  Indications: Psychot.disords., ac.mania episod., prev.recurr.manic   should occur at interv.of not less than 1 wk. Dos.range: 5-20 mg
       dur. init.dos.titrat., hypertens., ven.thromboembol., rhinit., dry mouth,   episod.of bipol.disord.  once dly. Incr.above routine 10 mg/day advis.only aft.clinic.assessm.
       constip., dyspeps., diarrh., jaund., hepatit., myalg., UTI, priapism, ga-  (S5) TABS, 43/2.6.5/0326, 0327, 0328  Ac.man.in bipol.disord: Init.dos:10 mg once dly. Dos.adjustm.
       lactorrh., asthen., periph. oed., ac.withdr. sympt., fev., weight gain.,   715994-001: 2,5 mg, 28, R358,75  within range of 5-20 mg/day to occur at interv.of not less than 24
       elev. ser.transamin./ cholesterol & triglyceride, decr.thyroid horm.lev.  715995-001: 5 mg, 28, R559,66  hrs.if indicat.
       Special precautions: Elderly esp.dur.init. dos.per., monit.gluc.  715996-001: 10 mg, 28, R717,50  Prev.recurr.in bipol.disord: Recomm.init.dos: 10 mg/ day. For those
       contr.of exist.diabet./ hyperglycaem.sympt.in those at risk, pts.who   (S5) RAPITABS, 43/2.6.5/0069, 0070  receiv.Olexar treatm.for manic episod.cont.ther.at same dos. Incr.dos.
       develop.hyperglycaem.sympt.dur.ther.should undergo fast.bld.gluc.  715967-001: 5 mg, 28, R636,65  to great.than recomm.start.dos.within range of 5-20 mg/day only aft.
       test, cont.anti-diab.meds. poss.necess.despite ther.discont., low.  715968-001: 10 mg, 28, R816,24  clinic.assessm.at interv.of not less than 24 hrs.
       effect.dos. in elderly when consid.essent.& caref.monit., benef./  Dosage: Recomm.continuat.at low.dos.need.to maint.remiss.in   Contra-indications: Known narrow-angl. glauc. risk, safety in
       risk assessm.in elderly pts.tak.stroke risk into account, known CV/  respond.pts. Take immed aft. open. placing in mouth/disperse in   pregn.& lactat.& childr.und.18 yrs. not est., concom.fluoxetine
       cerebrovasc.dis./ condits. predispos.to hypotens., consid.dos. re-  water/ beverage.  not recomm.
       duct./discont.ther.if tard.dyskines.S&S occur, discont.ther.& admin.  Psychot.disords: Admin.once dly. Init. 5-10 mg/ day with target   Side-effects: Neurolept.malign.syndr., tard. dyskines., incr.incid.of
       appropr.treatm.in case of neurolept.malign.syndr., concom.alcoh./  dos.of 10 mg/day within several days. Dos. incr.should not be con-  abnorm.gait/falls/urin. incontin./pneumon./death/CVA’s incl.stroke
       other central.act.meds., concom. antihypertens./meds. prolong.  sid.bef.1 wk.of ther. Dos.rang.from 5-20 mg as sngl.dly.dos. Dos. incr.  in elderly with dement.relat.psychos., trans. elev.liv.transaminase
       QTc interv., poss.dos.adjustm.with phenytoin/other concom.hepat.  above 10 mg advis.only aft.clinic.assessm. Consid.5 mg start.dos.for   plasma lev., bld.dyscras., weight gain, elev.prolact.& gluc.lev., water
       enzyme induc., reduc.dos.with non-induc.eg.sod.valproate, caref.   hepat.impairm./elderly.  intoxicat., diab.mellit., acidos., hyponatraem./-kalaemia./-glycaem.,
       assessm.of indiv.pt.in case of cont.treatm.at high. dos., seiz.hist.,   Ac.man.in bipol.disord: Recomm.dos: 10 mg once dly. Dos.ad-  hyperbilirubinaem./-cholesterolaem./-lipidaem./-uricaem., diab.aci-
       withdr.grad., ren./hepat. impairm.  justm.within range of 5-20 mg/ day to occur at interv.of not less   dos., goiter, ketosis, gout, hyperkalaem./-natraem., hypoproteinaem.,
       Drug interactions: Act.of dopaminerg. antagon., incr.clear.with   than 24 hrs.if indicat.
       concom. carbamazepine/ phenytoin/thioridazine, signific. incr.in   Prev.recurr.in bipol.disord: Recomm.init.dos: 10 mg/ day. For those   albuminur., CNS effs.incl.seiz., neuropsych.disords., hyperton., articu-
                                                                  lat.impairm., decr.libido, paraesthes., alcoh./tobacco misuse, withdr.
       quetiapine AUC with ketoconazole.  receiv.Oleanz for manic episod.cont. ther.at same dos. Incr.dos.over   syndr., taste pervers., incr.libido, fac. paralys., incoordinat., nystag-
       OLAWIN, (Sanofi-Aventis) Winthrop [P/S]  10 mg advis.only aft.clinic.assessm.& should occur at interv.of not   mus, neuropathy, encephalopathy, neuralg., eye disords.incl.ocul.
       Olanzapine                    less than 24 hrs. Safety of dos.above 20 mg/day not est.  musc.abnormal.& lens.pigment deposits, deafn., ear pain, tinnit.,
       Indications: Psychot.disords., ac.episod of mod.to sev.mania & pre-  Contraindications: Known narrow-angl.glauc risk, safety in pregn.&   orthostat.hypotens., CV disords. incl.HF/card.arrest & pulm.embol.,
       vent.recurr.manic episod.in bipol. disord.  lactat.& pts.und.18 yrs.not est., pts.with dement.-relat.psychos., con-  incr.cough, pharyngit., rhinit., dyspn., voice alterat., apnoea, aspirat.
       (S5) ORODISPERS.TABS, [P/S] 44/2.6.5/9854, 9855  com. fluoxetine not recomm., not recomm.in Parkinson’s dis.  pneumon., pneumon., laryngit., hyperventilat., asthma, atelectas.,
       721386-001: 5 mg, 30, R265,89  Side effects: Hyperprolactinaem., neurolept. malign. syndr., seiz.,   epistax., haeoptys., hiccup, stridor, lung oed., hypoventilat., hypox.,
       721390-001: 10 mg, 30, R261,41  tard.dyskines., incr.CVA effs. incl.stroke/fatalit., hyperglycaem.incl.  dysphag., GI disturbs.incl.intest.obstruct.& rect.haemorrh., tooth
       (S5) FILM-COAT.TABS, [P/S] 44/20.6.5/1020, 1021  keto-acidos./ hyperosmol.coma/death, bld.dyscras., allerg. reacts.incl.  caries, periodont.abscess, oral monillias., gingivit., hepatit., sweat.,
       721388-001: 5 mg, 30, R250,08  anaphylact., periph.oed., hypercholesterolaem., hypertriglyceridaem.,   rash, alopec., skin ulc./discolourat., seborrh., eczema, photosens.
       721389-001: 10 mg, 30, R335,28  hepatit., pancreatit., personal.disord., mood/ ment. chang., halluci-  reacts., hirsutism, musc.-skelet.& connect.tiss.disords, myasth., os-
       Dosage: Dissolv.orodisp.tab.in mouth. Take full glass of water im-  nat., agitat., akathis., dizzin., somnol., abnorm.gait, falls, anx., hostilit.,   teoporos., back-/bone pain, urin.disords., UTI, urin.incontin., menstr.
       med.aft.admin.OR dispers.in glass of water/suit.liq.immed bef.admin.   euphor., nervousn., trem., Parkinsonism, symptomatol., speech dis-  irreg., vaginit., abnorm.ejaculat., impot., priapism, breast pain, enlarg.
       The 10 mg orodisp.tab.may be halv.at break line.  ord., dyskines.incl. buccogloss. syndr./choreoathetos., dyston., resid.   uter.fibroids, vag. haemorrh., asthen., fev., dent.-/chest-/neck-/pelvic
       Psychot.disords: Admin.as sngl.dly.dos. Init. 5-10 mg/day with   effs. incl.movem.disord., myoclon., twitch., drowsin., headache, apa-  pain, fac.oed., hangover eff., intent.injury.
       target dos.of 10 mg/day within sever.days. Do not consid.dos.incr.  thy, confus., insomn., stutter., paraesthes., hyperton., water intoxic.,   Special precautions: Monit.exist.diab.for worsen. gluc.contr.,
       bef.1 wk. Dos. range from 5-20 mg/day. Dos.incr.over 10 mg/day   abnorm. vis., diplop., brady-/tachycard., ventric. extrasyst., palpitat.,   monit.pts.start.treatm.at risk of diab.for hyperglycaem., fast.bld.
       advis.only aft.clinic.assessm.  orthostat.hypotens., hypertens., ven.thromboembol., pneum., incr.   gluc.if hyperglycaem. develops, some pts.req.continuat. of anti-di-
       Ac.man.in bipol.disords: Admin.as sngl.dly.dos. gener.start.with   cough, pharyngit., dyspn., rhinit., GI disturbs., rash, acne, dry skin,   abet.treatm.despite discont., grad. discont., elev.prolact.lev.persist.
       10 mg. Dos.adjustm.with.dos. range of 5-20 mg/day if indic.should   photosens., sweat., asthen., extremit./ joint pain, rhabdomyolys.,   modestly dur. chron. admin., hist.of seiz./condits.assoc.with seiz. /
       occur at interv. of not less than 24 hrs.  urin.incont., vaginit., dysmenorrh., priapism, menstr.chang., decr. li-  low.seiz.thresh., predispos.risk fact.in elderly with dement.relat.psy-
       Prevent.recurr. of man.in bipol.disord: Recomm. start.dos: 10 mg/  bido, weight chang., fev., chest pain, flu-like sympt., incr.salivat., thirst,   chos.to incr.mortality incl. &gt;80 yrs. /sedat./concom.benzodiazepines
       day. For those receiv. Olawin for man.episod.cont.ther.for prevent.re-  angio-/fac.oed., discontinuat. react., exacerbat.of pre-exist.diab.  & resp.condits., S&S of hepat.impairm., pre-exist.condits.assoc. with
       curr. at same dos. Incr.dos. over 10 mg with.range of 5-20 mg/day   Special precautions: Effectiven.for more than 6 wks not est.,   limit.hepat.funct.reserve, concom.potent. hepatotox.meds., discont.
       advis.only aft.clinic.assessm.& should occur at interv.of not less than   period.re-assesm.to determ.need for maint. treatm., discont.grad.,   if hepatit.diagnos., concom. centr.act.agents & alcoh., concom.
       24 hrs. Safety of dos. above 20 mg/day not eval. Improvem.in clinic.   elev.prolact. lev.persist. modestly dur.chron admin., incr. mamma-  meds. known to incr.QTc interv./congenit.long QT syndr./ CHF/card.
       condit.poss.take sever.days/wks.  ry gland neoplasms in rodents consid. prolact. mediat., discont.if   hypertrophy/hypokalaem.& hypomagnesaem., symptomat.prostat.
       Contraindications:known narrow-angl.glauc. risk, safety & effic.   any clinic.NMS manifestat./high fev.observ., seiz.hist./condits. as-  enlargem., narr.angle glauc., paralyt.ileus & relat.condits., card.pts./
       in childr.und.18 yrs.not est., safety in pregn.& lactat. not est., effic.in   soc. with seiz./low.seiz.thresh., consid.discont. / dos.reduct.if tard.  condits.predispos.to hypotens.due to orthostat. hypotens.risk, elderly
       elderly pts.with dement.-relat.psychos.not est.  dyskines.S&S develop, tard. dyskines.risk incr.with longt.expos.&   with dement. and/Parkinson’s dis., condits.contrib.to core body temp.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page55.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page51.html">51</a>&nbsp;&nbsp;&nbsp;<a href="page52.html">52</a>&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>
             </td>
             <td width="35%"><a href="page57.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page57.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
